Literature DB >> 26870338

ADAMTS13 and 15 are not regulated by the full length and N-terminal domain forms of TIMP-1, -2, -3 and -4.

Cenqi Guo1, Anastasia Tsigkou1, Meng Huee Lee1.   

Abstract

A disintegrin and metalloproteinase with thombospondin motifs (ADAMTS) 13 and 15 are secreted zinc proteinases involved in the turnover of von Willebrand factor and cancer suppression. In the present study, ADAMTS13 and 15 were subjected to inhibition studies with the full-length and N-terminal domain forms of tissue inhibitor of metalloproteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit the ADAMTS proteinases in the full-length or N-terminal domain form. While ADAMTS13 is also not sensitive to the hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 can be effectively inhibited by batimastat (Kiapp 299 nM). In conclusion, the present results indicate that TIMPs are not the regulators of these two ADAMTS proteinases.

Entities:  

Keywords:  a disintegrin and metalloproteinase; a disintegrin and metalloproteinase with thombospondin type 1 motifs; enzyme inhibition; matrix metalloproteinase; tissue inhibitors of metalloproteinases

Year:  2015        PMID: 26870338      PMCID: PMC4726870          DOI: 10.3892/br.2015.535

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  24 in total

1.  The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.

Authors:  A Amour; C G Knight; A Webster; P M Slocombe; P E Stephens; V Knäuper; A J Docherty; G Murphy
Journal:  FEBS Lett       Date:  2000-05-19       Impact factor: 4.124

2.  TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).

Authors:  M Kashiwagi; M Tortorella; H Nagase; K Brew
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

3.  Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5.

Authors:  Lidia Mosyak; Katy Georgiadis; Tania Shane; Kristine Svenson; Tracy Hebert; Thomas McDonagh; Stewart Mackie; Stephane Olland; Laura Lin; Xiaotian Zhong; Ronald Kriz; Erica L Reifenberg; Lisa A Collins-Racie; Christopher Corcoran; Bethany Freeman; Richard Zollner; Tod Marvell; Matthew Vera; Phaik-Eng Sum; Edward R Lavallie; Mark Stahl; William Somers
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

4.  Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.

Authors:  Stefan Gerhardt; Giles Hassall; Paul Hawtin; Eileen McCall; Liz Flavell; Claire Minshull; David Hargreaves; Attilla Ting; Richard A Pauptit; Andrew E Parker; W Mark Abbott
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

5.  Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme.

Authors:  Meng-Huee Lee; Vandana Verma; Klaus Maskos; Deepa Nath; Vera Knäuper; Philippa Dodds; Augustin Amour; Gillian Murphy
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

6.  A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.

Authors:  R Grillberger; B Gruber; S Skalicky; G Schrenk; P Knöbl; B Plaimauer; P L Turecek; F Scheiflinger; H Rottensteiner
Journal:  J Thromb Haemost       Date:  2014-07-29       Impact factor: 5.824

7.  Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.

Authors:  H B Feys; N Vandeputte; R Palla; F Peyvandi; K Peerlinck; H Deckmyn; H R Lijnen; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

8.  Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer.

Authors:  Cristina G Viloria; Alvaro J Obaya; Angela Moncada-Pazos; María Llamazares; Aurora Astudillo; Gabriel Capellá; Santiago Cal; Carlos López-Otín
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

9.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

Authors:  A Amour; P M Slocombe; A Webster; M Butler; C G Knight; B J Smith; P E Stephens; C Shelley; M Hutton; V Knäuper; A J Docherty; G Murphy
Journal:  FEBS Lett       Date:  1998-09-11       Impact factor: 4.124

10.  ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma.

Authors:  Sarah Porter; Paul N Span; Fred C G J Sweep; Vivianne C G Tjan-Heijnen; Caroline J Pennington; Tanja X Pedersen; Morten Johnsen; Leif R Lund; John Rømer; Dylan R Edwards
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

View more
  4 in total

1.  Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use.

Authors:  Bingjie Jiang; Yuewei Xu; Yihe Zhang; Meng Huee Lee
Journal:  Mol Cell Biol       Date:  2019-08-27       Impact factor: 4.272

2.  Proteomic discovery of substrates of the cardiovascular protease ADAMTS7.

Authors:  Alain Colige; Christine Monseur; James T B Crawley; Salvatore Santamaria; Rens de Groot
Journal:  J Biol Chem       Date:  2019-03-29       Impact factor: 5.157

3.  ADAMTS proteases in cardiovascular physiology and disease.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Open Biol       Date:  2020-12-23       Impact factor: 6.411

Review 4.  The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review.

Authors:  Ulf Schött; Cristina Solomon; Dietmar Fries; Peter Bentzer
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-04-12       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.